Sign In  |  Register  |  About Burlingame  |  Contact Us

Burlingame, CA
September 01, 2020 10:18am
7-Day Forecast | Traffic

  • Search Hotels in Burlingame

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Illumina Inc (NQ: ILMN )

136.99 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Illumina Inc

< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
29 30 Next >
Lowey Dannenberg, P.C. is Investigating Illumina, Inc. (NASDAQ: ILMN) for Potential Breaches of Fiduciary Duty by Its Board of Directors
From Lowey Dannenberg, P.C.
Via GlobeNewswire
Nike To Rally Around 53%? Here Are 10 Other Analyst Forecasts For Friday
Piper Sandler cut the price target for Accenture plc (NYSE: ACN) from $312 to $300. Piper Sandler analyst Arvind Ramnani maintained a Neutral rating. Accenture shares rose 0.3% to $301.56 in pre-market... 
Via Benzinga
Expert Ratings for Illumina
Via Benzinga
September's Shakeout: S&P 500, Nasdaq 100 See Just 13% Of Stocks Above 50-Day Average
The September market downturn is spreading like wildfire across various sectors, with only a handful of stocks managing to maintain the positive trend seen in recent months. 
Via Benzinga
Topics Stocks
Exposures US Equities
How Is The Market Feeling About Illumina?
Via Benzinga
Is the Worst Over for Illumina Stock?
There's reason to believe that the future is starting to look better. 
Via The Motley Fool
$100 Invested In Illumina 20 Years Ago Would Be Worth This Much Today
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 28, 2023
Via Benzinga
Myriad Genetics and Illumina Achieve Milestones in Strategic Partnership to Support Biopharma Clinical Trials
Myriad can conduct prospective clinical trials using Illumina’s TruSight Oncology Comprehensive Investigational Use Only test 
From Myriad Genetics, Inc.
Via GlobeNewswire
11 Analysts Have This to Say About Illumina
Via Benzinga
Cramer Is 'Astonished' That Chewy Is 'Doing This Poorly — So Many Of Us Use It'
On CNBC’s "Mad Money Lightning Round," Jim Cramer said yes to The St. Joe Company (NYSE: JOE). "I’ve liked St. Joe forever," he added. 
Via Benzinga
AI Integration In Biotech & Pharma: Companies Positioned To Benefit
The convergence of artificial intelligence (AI) with the biotech and pharmaceutical sectors is ushering in a new era of innovation. AI is catalyzing transformations from drug discovery to patient care.... 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Did Elon Musk Admit 90% Decline In Twitter's Value Since Acquisition?, Apple's Zero-Click Vulnerabilities Uncovered By Internet Watchdog Group, Gas Prices Jump As Strikes Start At Major Chevron Australia LNG Projects: Today's Top Stories
Benzinga 
Via Benzinga
Peering Into Illumina's Recent Short Interest
Via Benzinga
Here's How Much You Would Have Made Owning Illumina Stock In The Last 20 Years
Via Benzinga
Elliott Wave Technical Analysis: Illumina Inc.
Looking for shorts with invalidation at $195. 
Via Talk Markets
Billionaire Activist Investor Carl Icahn Shows Support For Illumina's Newly Appointed CEO
Activist investor Carl Icahn has thrown his support behind Illumina Inc's (NASDAQ: ILMN) new CEO, Jacob Thaysen, providing a sigh of relief for the company as it strives to recover from a contentious... 
Via Benzinga
Cathie Wood's Buying These 3 Stocks Hand Over Fist
A drugmaker, a gene sequencer, and a streaming business all made deep impressions on Ark Invest's stock-picking team. 
Via The Motley Fool
Why Is Illumina Stock Trading Lower Today?
Illumina Inc (NASDAQ: ILMN) shares are trading lower after the company appointed Jacob Thaysen as its new CEO, roughly three months after the company parted ways  
Via Benzinga
Wall Street Thinks Illumina Stock Will Rise 27% in 1 Year. Here's Why That Probably Won't Happen.
Its core revenue won't grow, and that's not even its biggest problem at the moment. 
Via The Motley Fool
Down 15% in 2023, Should You Buy the Dip With Illumina Stock?
Illumina's future is looking a bit dim at the moment. 
Via The Motley Fool
The Latest Analyst Ratings for Illumina
Via Benzinga
Illumina Unusual Options Activity
Via Benzinga
Goldman Sachs Reveals Long-Term AI Portfolio: Here Are The 50 Stocks To Monitor
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Why Illumina Shares Are Falling Today
Illumina Inc (NASDAQ: ILMN) disclosed in an SEC filing that the Securities and Exchange Commission is the latest government agency investigating the company's  
Via Benzinga
Topics Regulatory Compliance
Exposures Legal Regulatory
Illumina To Bear The Brunt Of Slowdown In Consumables Purchasing Amid Lower Demand In China: Analyst
Stifel analyst Daniel Arias reiterated a Buy rating on Illumina, Inc (NASDAQ: ILMN), 
Via Benzinga
Alibaba, Illumina, CyberArk Software And Other Big Stocks Moving Higher On Thursday
U.S. stocks traded higher, with the Dow Jones gaining around 350 points on Thursday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Topics Stocks
Exposures US Equities
Nasdaq, S&P 500 Futures Rally Ahead Of Inflation Data; Why This Analyst Sounds Out Caution About Stock Valuations
Via Benzinga
Topics Economy Stocks
Exposures Interest Rates US Equities
Disney, Alibaba And 3 Stocks To Watch Heading Into Thursday
With U.S. stock futures trading higher this morning on Thursday, some of the stocks that may grab investor focus today are as follows: 
Via Benzinga
Illumina Stock Crumbles As Earnings Guidance Completely Misses Forecasts
Illumina beat second-quarter expectations, but earnings guidance completely missed. 
Via Investor's Business Daily
< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
29 30 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Burlingame.com & California Media Partners, LLC. All rights reserved.